Composition:
Solifenacin succinate 1 mg/mL oral suspension 

 

Therapeutic indications: 
- Neurogenic detrusor overactivity: 

Urginafect oral suspension is indicated for the treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 2 to 18 years. 
- Overactive bladder in adults: 

Urginafect oral suspension is indicated for symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder (OAB) syndrome.